Pfenex Inc. - Investors http://pfenex.investorroom.com/ Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis http://pfenex.investorroom.com/news-releases?item=132 Submitted as a 505(b)(2) NDA with an Expected Ten-Month Review Mon, 10 Dec 2018 08:05:00 -0500 http://pfenex.investorroom.com/news-releases?item=132 Pfenex Reports Third Quarter Results and Provides Business Update http://pfenex.investorroom.com/news-releases?item=131 On track to submit the NDA for PF708 to the FDA in fourth quarter of 2018 Wed, 07 Nov 2018 16:05:00 -0500 http://pfenex.investorroom.com/news-releases?item=131 Pfenex to Host Conference Call and Webcast Reporting Third Quarter Financial Results on Wednesday, November 7 http://pfenex.investorroom.com/news-releases?item=130 Thu, 25 Oct 2018 16:05:00 -0400 http://pfenex.investorroom.com/news-releases?item=130 Pfenex Reports New Employment Inducement Award Under NYSE American Listing Rules http://pfenex.investorroom.com/news-releases?item=129 Mon, 01 Oct 2018 16:10:00 -0400 http://pfenex.investorroom.com/news-releases?item=129 Pfenex to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference http://pfenex.investorroom.com/news-releases?item=128 Fri, 21 Sep 2018 17:03:00 -0400 http://pfenex.investorroom.com/news-releases?item=128